Thirty normal subjects were given a single loading dose of warfarin sodium, 1.5 mg/ kg of body weight. The drug was metabolized slowly (mean biological half-life, 47 hr) and showed a prolonged biological effect (over 6 days). In two separate experiments no loading dose was given; instead, daily doses of 15 mg and 10 mg were administered to 15 of the subjects. The prothrombin complex responses were compared with those obtained in the same subjects after the large loading dose. The mean time in days to reach the therapeutic range (prothrombin complex activity < 35% of normal) was 1.1 days with the dose of 1.5 mg/kg of body weight, 2.7 days with the dose of 15 mg/day, and 5.2 days with 10 mg/day. With all three methods the therapeutic range was reached soon after a level of warfarin of 2 mg/L plasma was attained.
T HERAPY with oral anticoagulant drugs is usually initiated with a large loading dose; the size of subsequent daily doses is adjusted according to prothrombin test responses until a stable maintenance level is reached.' The large initial dose is used to produce the greatest anticoagulant effect in the shortest time possible. However, this method of initiating therapy may lead to an excessive and dangerous degree of anticoagula-tion in some patients. The rapid absorption and slow metabolism of warfarin sodium and the prolonged biological effect from a single dose suggested to us that drug levels adequate for therapeutic response could be achieved without a large loading dose. 2 3 We have therefore studied the effect of initiating treatment with daily doses only slightly larger than the anticipated maintenance dose. This method minimizes the danger of excessive anticoagulation yet delays the development of the therapeutic effect only slightly if at all.
Methods
Thirty normal men and women, 21 remained above 2 mg/L for over 120 hr. In all cases the prothrombin complex activity was significantly reduced by 24 hr, was well within the "therapeutic range" (<35% of normal) by 36 hr, and reached a maximum reduction between 36 and 96 hr. The mean reduction in prothrombin complex activity was maximum at 48 hr and remained within the therapeutic range through the 120-hr period of observation.
The warfarin concentrations in plasma and the effects on the prothrombin complex activity in the experiments in which no loading dose was administered are reported in tables The means of the plasma drug concentrations and prothrombin complex activity responses obtained with the three dosages are shown in figure 1 .
The rates of fall of the four vitamin K-dependent clotting factors (II, VII, IX, and X) after the loading dose and during the daily dosage of 15 mg were compared in six of the subjects. The percentage value that each factor was reduced from its pretreatment value (taken as 100%) is given in table 5. The only factor which showed a significant difference was factor VII; at 24 length of time that the drug will remain in the plasma in a concentration above the level required for the suppression of new clotting factor production. The longer the drug is present above this level, the greater is the degree and the duration of response. No significant difference in the inherent ability of the various coumarin and indanedione anticoagulant drugs to produce this maximum rate response has been noted. 12 The degree and duration of response, however, vary with the rate of absorption and the metabolic halflife of the drug: compounds that are absorbed and disappear rapidly from the blood produce a lesser maximum degree of clotting factor depression and a faster return to normal; drugs that are absorbed and disappear at slower rates have a longer time to act and hence produce a greater maximum degree of clotting factor depression and a slower return to normal. 13 It is customary to use large loading doses of the oral anticoagulant drugs to produce a rapid prolongation of the prothrombin time.
When warfarin sodium was introduced into clinical therapeutics, the recommended initial loading dose was about 1 mg/kg of body weight. This amount of warfarin represents a more potent dose than the usual loading dose of 300 mg of dicumarol; this, rather than any inherent difference between the drugs, is probably responsible for the more rapid onset of the effect of warfarin than of dicumarol in clinical practice. 7' 13 An occasional patient with a normal functioning hemostatic mechanism and many patients who have recently undergone major surgery or are elderly, septic, malnourished, debilitated, or suffer from liver disease or congestive heart failure respond excessively to a loading dose of 1 mg of warfarin/kg of body weight. The principal advantage of initiating therapy with the small daily dosage is that there is less danger of producing an excessive effect in a sensitive patient. This method also avoids any marked difference between the size of dose used to initiate therapy and that required to maintain it. This is desirable with such drugs as warfarin Circulation, Volume XXXVIII, July 1968 which have long biological half-lives.
The main argument against the small daily dosage method for initiating therapy is that there is a delay in achieving the desired level of prothrombin complex activity. However, most of our subjects who received 15 24 Marcus and associates recently reported that the blood levels of digoxin in man24 and the blood and tissue levels of digoxin in the dog25 were the same by the end of 6 days whether therapy was initiated with or without a loading dose. It appears that drugs like warfarin and digoxin, which have very long biological half-lives, will accumulate sufficiently in the blood for therapeutic effect when given daily without a loading dose.
